Published on

Urology – Localized Prostate Cancer (T1–T2)

Epidemiology, Risk Factors, Diagnosis, Risk Stratification, Active Surveillance, Radical Prostatectomy, Radiotherapy, and Prognosis

1. Definition and Clinical Overview

Localized prostate cancer is histologically confirmed adenocarcinoma of the prostate that is clinically confined to the prostate gland, without evidence of regional lymph node involvement or distant metastasis.

TNM Classification

  • T1: Clinically inapparent prostate tumour.
  • T2: Tumour clinically confined to the prostate.
  • N0: No regional lymph node metastases.
  • M0: No distant metastases.

Clinical Importance

Localized prostate cancer encompasses a broad spectrum of disease, ranging from indolent tumours that may never cause symptoms to aggressive cancers requiring definitive treatment.

Management depends on:

  • PSA concentration.
  • ISUP Grade Group.
  • Clinical tumour stage.
  • Cancer volume.
  • MRI findings.
  • Life expectancy.
  • Comorbidities.
  • Baseline urinary and sexual function.
  • Patient preferences.

Key Clinical Principle: Localized Prostate Cancer Requires Risk-Adapted Management Because Not Every Diagnosed Cancer Requires Immediate Curative Treatment.


2. Epidemiology

Historical United States Statistics

The original source reports the following American Cancer Society estimates for 2014:

  • 233,000 new prostate cancer cases.
  • 29,480 prostate cancer deaths.

These are historical figures and do not represent current annual incidence or mortality.

Proportion of Localized Disease

The source reports that approximately:

81% of newly diagnosed prostate cancers were localized.

Clinical Importance

Localized prostate cancer accounts for a substantial proportion of newly diagnosed prostate malignancies, particularly in populations undergoing PSA-based early detection.


3. Age-Related Prevalence

The historical source describes a strong relationship between age and the prevalence of prostate cancer.

Historical Estimates

  • Age 50–60 years: approximately 44%.
  • Age 70–80 years: approximately 83%.
  • Worldwide figures: approximately 20–35%.

Important Qualification

These unusually high percentages are more consistent with occult or histologically detected prostate cancer in selected studies than with the prevalence of clinically diagnosed disease.

They should not be interpreted as meaning that 83% of all men aged 70–80 have clinically significant prostate cancer.

Clinical Importance

The Frequency Of Histological Prostate Cancer Increases Markedly With Age, But Many Tumours Remain Clinically Indolent.


4. Risk Factors

Increasing Age

Age is one of the strongest predictors of prostate cancer.

Clinical Significance

The probability of detecting prostate cancer increases substantially in older men.


5. Family History

A family history of prostate cancer increases individual risk.

Highest-Risk Relationships

First-degree relatives, including:

  • Father.
  • Brother.
  • Son.

Important Considerations

Risk increases with:

  • Multiple affected relatives.
  • Diagnosis at a younger age.
  • Strong clustering of prostate cancer within a family.

Associated Familial Cancers

The historical source also identifies possible associations with familial breast cancer.

Contemporary Explanation

Some inherited pathogenic variants, particularly BRCA2, may predispose to both breast and prostate cancer.

Clinical Importance

A Strong Family History Of Prostate Or Breast Cancer Should Prompt Consideration Of Hereditary Cancer Risk.


6. Population-Based Risk Differences

The historical source reports that African American men had approximately:

  • 40% higher prostate cancer incidence.
  • 2.4 times the risk of prostate cancer mortality.

Important Qualification

These are historical population-level estimates.

Differences in incidence and mortality involve multiple factors, including:

  • Genetic susceptibility.
  • Screening access.
  • Healthcare access.
  • Socioeconomic conditions.
  • Treatment disparities.
  • Environmental influences.

Population ancestry should not be treated as a deterministic predictor of disease in an individual.


7. Genetic Factors

The historical chapter refers to general prostate cancer genetics.

Important Contemporary Germline Associations

  • BRCA2.
  • BRCA1.
  • ATM.
  • CHEK2.
  • HOXB13.
  • Selected mismatch-repair genes associated with Lynch syndrome.

Clinical Importance

Inherited pathogenic variants may influence:

  • Prostate cancer susceptibility.
  • Screening recommendations.
  • Tumour aggressiveness.
  • Family counseling.
  • Treatment selection in advanced disease.


8. Pathophysiology

Prostate cancer develops through malignant transformation of prostatic epithelial cells.

Contributing Biological Factors

  • Genetic predisposition.
  • Chronic inflammatory processes.
  • Oxidative stress.
  • Accumulated cellular DNA abnormalities.
  • Altered androgen receptor signaling.

Important Qualification

The historical source identifies inflammation and oxidative stress as potential contributing factors rather than proven causes of every prostate cancer.


9. Associated Conditions

Benign Prostatic Hyperplasia

BPH.

BPH and prostate cancer may coexist.

Important Distinction

BPH is not itself prostate cancer.

Lower Urinary Tract Symptoms

LUTS.

Possible symptoms include:

  • Urinary frequency.
  • Urgency.
  • Weak stream.
  • Hesitancy.
  • Nocturia.

Clinical Importance

Lower Urinary Tract Symptoms In A Patient With Localized Prostate Cancer Are Often Related To Coexisting BPH Rather Than The Cancer Itself.

Obesity

The historical source identifies obesity among associated conditions.

Obesity may influence general health, treatment outcomes, and aspects of prostate cancer risk.


10. Prevention and Chemoprevention

No medication is routinely recommended solely for the primary prevention of prostate cancer in otherwise healthy men.

The historical source discusses major prevention trials.


11. Finasteride and the PCPT Trial

Medication

Finasteride.

Drug Class

5-alpha-reductase inhibitor.

Historical Trial

Prostate Cancer Prevention Trial.

Reported Finding

Approximately:

25% reduction in prostate cancer diagnoses.

Historical Concern

A greater proportion of detected cancers were high-grade.

Important Qualification

Subsequent analyses indicate that changes in prostate size and cancer detection contributed to the apparent high-grade cancer signal.

Finasteride is not routinely prescribed solely to prevent prostate cancer.


12. Dutasteride and the REDUCE Trial

Medication

Dutasteride.

Drug Class

5-alpha-reductase inhibitor.

Historical Finding

Approximately:

27% reduction in prostate cancer diagnoses.

Important Qualification

A lower diagnosis rate does not necessarily demonstrate reduced prostate cancer mortality.

Routine chemoprevention with dutasteride is not established.


13. Selenium and Vitamin E

SELECT Trial

The source describes investigation of:

  • Selenium.
  • Vitamin E.

Main Finding

No established prostate cancer prevention benefit.

Subsequent Observation

Vitamin E supplementation was associated with approximately:

17% increased prostate cancer risk.

Important Qualification

This figure relates to the vitamin E treatment arm and should not be interpreted as an identical increase caused by selenium.

Clinical Importance

Vitamin E And Selenium Supplements Should Not Be Recommended As Proven Prostate Cancer Prevention Strategies.


14. Clinical Presentation

General Principle

Localized prostate cancer is usually asymptomatic.

Common Routes to Diagnosis

  • Elevated PSA.
  • Suspicious digital rectal examination.
  • MRI abnormalities.
  • Prostate biopsy.

Clinical Importance

Most Localized Prostate Cancers Are Detected Before Symptoms Develop.


15. Lower Urinary Tract Symptoms

Possible symptoms include:

  • Frequency.
  • Urgency.
  • Hesitancy.
  • Reduced urinary stream.
  • Incomplete bladder emptying.

Important Consideration

These symptoms are more commonly caused by benign prostatic enlargement than localized prostate cancer.


16. Symptoms Suggesting Advanced Disease

The historical source emphasizes:

  • Unintentional weight loss.
  • Newly developed skeletal pain.

Clinical Importance

New Bone Pain Or Unexplained Weight Loss In A Patient With Prostate Cancer Should Raise Concern For Disease Beyond The Prostate.

Such symptoms warrant appropriate clinical assessment.


17. Physical Examination

Digital Rectal Examination

DRE.

Clinical T1 Disease

No palpable malignant prostate nodule.

Clinical T2 Disease

A palpable tumour or nodule confined to the prostate.

Findings Suggesting More Advanced Disease

  • Loss of normal lateral sulcus definition.
  • Palpable seminal vesicle involvement.
  • Fixation to surrounding structures.

Clinical Importance

A Palpable Prostate Nodule Confined To The Gland Is Consistent With Clinical T2 Disease.

Important Limitation

A normal DRE does not exclude clinically significant cancer.


18. Prostate-Specific Antigen

Definition

PSA is a protein produced by prostatic epithelial cells.

Historical PSA Half-Life

Approximately:

2–3 Days.

Main Clinical Uses

  • Prostate cancer risk assessment.
  • Investigation of suspected malignancy.
  • Treatment monitoring.
  • Detection of recurrence.

Clinical Importance

PSA Is Prostate-Specific But Not Cancer-Specific.


19. Interpretation of Elevated PSA

Higher PSA values generally increase the probability of prostate cancer.

However, PSA may also be elevated by:

  • BPH.
  • Acute prostatitis.
  • Chronic prostatitis.
  • Urinary tract infection.
  • Urinary retention.
  • Recent relevant instrumentation.

Clinical Importance

PSA must be interpreted as a continuous risk marker rather than a definitive cancer test.


20. Historical PSA Screening Recommendations

The original chapter summarizes the 2013 AUA recommendations.

Men Younger Than 40 Years

Routine screening was not recommended.

Average-Risk Men Aged 40–54 Years

Routine screening was generally discouraged.

Higher-Risk Men Younger Than 55 Years

Individualized screening decisions.

Men Aged 55–69 Years

Shared decision-making.

Routine Screening Interval

Approximately every two years.

Men Older Than 70 Years or With Limited Life Expectancy

Routine screening was generally discouraged.

Important Qualification

These are historical screening recommendations. Modern screening is more explicitly risk-adapted and considers family history, genetic predisposition, ancestry-associated population risk, and life expectancy.


21. Contemporary Risk-Adapted PSA Testing

Current European guidance recommends informed early PSA testing from approximately:

  • 50 years: Average-risk men.
  • 45 years: Men with relevant family history.
  • 45 years: Men of African descent.
  • 40 years: BRCA2 pathogenic variant carriers.

Clinical Importance

Screening should aim to identify clinically significant cancer while minimizing overdiagnosis and unnecessary biopsy.


22. PSA Velocity

Definition

The rate of PSA change over time.

Historical Threshold

The source identifies PSA velocity greater than:

2 ng/mL per year

as an adverse prognostic finding.

Important Qualification

PSA velocity is not sufficiently reliable to serve as the sole indication for biopsy.


23. PSA Doubling Time

Definition

The interval required for PSA to double.

Clinical Role

More useful for assessing progression after diagnosis or treatment than as an isolated initial biopsy decision tool.


24. Percentage Free PSA

Definition

The percentage of circulating PSA present in the unbound form.

Historical Threshold

Free PSA Below 10%.

Historical Cancer Risk Estimate

Approximately:

56%.

Important Qualification

This probability applies to a historical studied population and depends on the total PSA level and clinical setting.

Clinical Importance

A Lower Percentage Free PSA Is Associated With A Greater Probability Of Prostate Cancer.


25. PSA Density

Definition

PSA divided by prostate volume.

Formula

PSA Density = Serum PSA / Prostate Volume.

Historical Threshold

0.15 ng/mL/cm³.

Clinical Significance

Higher PSA density increases concern for clinically significant prostate cancer.

Important Qualification

The source contains an inconsistent unit expression. PSA density is conventionally expressed as ng/mL/cm³.


26. PCA3 Urine Assay

Definition

A urine-based molecular test assessing prostate cancer antigen 3 expression.

Historical Clinical Role

The source describes possible usefulness when deciding whether to repeat biopsy after a previous negative result.

Contemporary Qualification

PCA3 is one of several available adjunctive biomarkers and is not a universal requirement in modern MRI-based diagnostic pathways.


27. Imaging in Localized Prostate Cancer

Historical Recommendations

The source summarizes the 2014 NCCN approach.

Low-Risk Disease

No routine metastatic staging imaging.

Bone Scan

Historically considered when:

  • PSA exceeded 10 ng/mL.
  • Gleason score was 8 or higher.

Pelvic CT or MRI

Historically considered when estimated nodal involvement exceeded approximately:

10%.

Important Qualification

These thresholds reflect historical staging practice.

Modern imaging decisions incorporate contemporary risk classification and PSMA PET availability.


28. Multiparametric MRI

Current Role

Prostate MRI is recommended before biopsy in patients with suspected organ-confined disease.

Main Objectives

  • Identify suspicious lesions.
  • Estimate tumour extent.
  • Guide targeted biopsy.
  • Improve detection of clinically significant cancer.
  • Help avoid unnecessary biopsy in selected low-risk situations.

Clinical Importance

Prebiopsy Prostate MRI Is A Major Component Of The Contemporary Diagnostic Pathway.


29. PI-RADS

Definition

Prostate Imaging Reporting and Data System.

Categories

  • PI-RADS 1: Very low suspicion.
  • PI-RADS 2: Low suspicion.
  • PI-RADS 3: Equivocal.
  • PI-RADS 4: High suspicion.
  • PI-RADS 5: Very high suspicion.

Clinical Importance

MRI findings should be interpreted alongside PSA density and other clinical risk factors.


30. Metastatic Staging

Conventional Modalities

  • CT abdomen and pelvis.
  • Bone scintigraphy.

Contemporary Molecular Imaging

PSMA PET/CT.

Clinical Role

More sensitive assessment of:

  • Pelvic lymph node metastases.
  • Distant lymph node metastases.
  • Bone metastases.
  • Other metastatic disease.

Contemporary Principle

PSMA PET/CT is recommended for appropriate high-risk localized disease when available and may be considered in selected unfavorable intermediate-risk disease.

Clinical Importance

Routine Metastatic Staging Is Usually Unnecessary In Low-Risk Localized Prostate Cancer.


31. Historical ProstaScint Imaging

The original source states that ProstaScint was not indicated for localized disease.

Contemporary Qualification

ProstaScint is an older imaging technique that has largely been replaced by modern PSMA PET-based imaging.


32. Prostate Biopsy

Diagnostic Principle

Histopathological examination is required to establish the diagnosis of prostate adenocarcinoma in the usual clinical pathway.

Historical Biopsy Technique

The source describes:

  • Transrectal or transperineal needle biopsy.
  • Ultrasound guidance.
  • 18-gauge needle.
  • Approximately 10–12 cores.
  • Laterally directed systematic sampling.


33. Local Anesthesia

Historical Method

Periprostatic local anesthetic injection.

Clinical Purpose

Reduce procedural discomfort.

Contemporary Context

Both transrectal and transperineal biopsy may be performed under appropriate local anesthesia.


34. Transperineal Versus Transrectal Biopsy

Transrectal Biopsy

The needle passes through rectal mucosa.

Important Limitation

Potential transfer of intestinal bacteria into prostate tissue or blood.

Transperineal Biopsy

The needle passes through perineal skin.

Main Advantage

Lower infectious complication risk.

Contemporary Recommendation

The Transperineal Route Is Preferred In Current European Guidance.


35. Antibiotic Prophylaxis

Historical Source

The chapter states that prophylactic antibiotics are always recommended.

Historical Infection Rate

Approximately:

0.5–1%.

Contemporary Qualification

Antibiotic prophylaxis differs by biopsy route.

  • Low-risk transperineal biopsy may be performed without routine prophylaxis in suitable patients.
  • Transrectal biopsy generally requires prophylaxis and appropriate rectal antisepsis.

Clinical Importance

The Historical Recommendation For Antibiotics In Every Prostate Biopsy No Longer Applies Universally.


36. MRI-Targeted Biopsy

Contemporary Approach

MRI-defined lesions can be sampled through:

  • Cognitive targeting.
  • MRI–ultrasound fusion.
  • Direct MRI-guided biopsy.

Additional Sampling

Targeted biopsy may be combined with perilesional or systematic cores.

Clinical Importance

MRI-directed biopsy improves anatomical targeting of suspicious prostate lesions.


37. Histopathology

Important pathological findings include:

  • Gleason score.
  • ISUP Grade Group.
  • Percentage of cores positive.
  • Tumour length within biopsy cores.
  • Perineural invasion.
  • High-grade prostatic intraepithelial neoplasia.
  • Other adverse histological patterns.


38. Gleason Grading

General Principle

The Gleason score describes glandular architectural patterns.

Important Examples

  • Gleason 3 + 3 = 6.
  • Gleason 3 + 4 = 7.
  • Gleason 4 + 3 = 7.
  • Gleason 4 + 4 = 8.
  • Gleason 4 + 5 = 9.

Clinical Importance

Gleason 4 + 3 Disease Has A Less Favorable Prognosis Than Gleason 3 + 4 Disease.


39. ISUP Grade Groups

Grade Group 1

Gleason 3 + 3 = 6.

Grade Group 2

Gleason 3 + 4 = 7.

Grade Group 3

Gleason 4 + 3 = 7.

Grade Group 4

Gleason score 8.

Grade Group 5

Gleason scores 9–10.

Clinical Importance

Grade Group is a major determinant of treatment selection and oncological prognosis.


40. Tumour Volume on Biopsy

Important parameters include:

  • Number of positive cores.
  • Percentage of positive cores.
  • Maximum cancer involvement in an individual core.
  • Percentage of Gleason pattern 4.

Clinical Importance

Low-volume disease is particularly relevant when assessing eligibility for active surveillance.


41. Perineural Invasion

Definition

Cancer cells extending around or along peripheral nerves.

Clinical Importance

May contribute to pathological risk assessment.

Important Qualification

Perineural invasion alone does not automatically indicate extraprostatic extension or require immediate radical treatment.


42. Extraprostatic Extension

The source includes extraprostatic extension among pathological findings.

Clinical Importance

True extension beyond the prostatic capsule represents disease beyond the clinical definition of organ-confined T1–T2 cancer.

Important Qualification

Clinical stage and pathological stage may differ.

A patient initially classified clinically as T1–T2 may later be found to have pathological T3 disease following radical prostatectomy.


43. Differential Diagnosis

Abnormal DRE

Possible causes include:

  • Prostate cancer.
  • Granulomatous prostatitis.
  • Prostatic cyst.
  • Prostatic calcification.
  • Other inflammatory or benign changes.

Elevated PSA

Important causes include:

  • BPH.
  • Urinary tract infection.
  • Acute prostatitis.
  • Chronic prostatitis.
  • Recent relevant instrumentation.

Clinical Importance

Neither An Elevated PSA Nor An Abnormal DRE Alone Confirms Prostate Cancer.


44. Treatment Principles

Before choosing treatment, assess:

  1. Cancer biology.
  2. Clinical risk category.
  3. Life expectancy.
  4. Overall health and frailty.
  5. Urinary symptoms.
  6. Erectile function.
  7. Patient goals and preferences.

Main Treatment Options

  • Active surveillance.
  • Watchful waiting.
  • Radical prostatectomy.
  • External-beam radiotherapy.
  • Brachytherapy.
  • Selected ablative treatments within appropriate specialist frameworks.


45. Historical Risk Classification

The original source describes three broad categories.

Low Risk

  • PSA below 10 ng/mL.
  • Gleason score 6 or lower.
  • Clinical T1c–T2a.

Intermediate Risk

  • PSA greater than 10–20 ng/mL.
  • Gleason score 7.
  • Clinical T2b.

High Risk

  • PSA greater than 20 ng/mL.
  • Gleason score 8–10.
  • Clinical T2c in the historical scheme.

Important Qualification

The source's categorization is historical and partly differs from contemporary EAU and NCCN classifications.

Modern systems incorporate Grade Groups, multiple intermediate-risk factors, and more refined clinical staging.


46. Contemporary Risk Stratification

Low-Risk Disease

Generally:

  • ISUP Grade Group 1.
  • PSA below 10 ng/mL.
  • Favorable localized clinical stage.

Favorable Intermediate Risk

May include low-volume Grade Group 2 cancer with favorable clinical characteristics.

Unfavorable Intermediate Risk

Includes more adverse intermediate-risk features, such as Grade Group 3 or multiple unfavorable criteria.

High-Risk Localized Disease

May include:

  • Grade Group 4–5.
  • PSA greater than 20 ng/mL.
  • Other high-risk features within a localized clinical stage.

Clinical Importance

Patients With The Same Clinical T Stage May Require Very Different Management Depending On PSA, Grade Group, And Tumour Burden.


47. Life Expectancy

More Than 10 Years

Patients with clinically significant localized cancer may benefit from curative treatment.

Less Than 10 Years

Watchful waiting may be more appropriate in selected asymptomatic patients, particularly with substantial competing health risks.

Important Principle

Life expectancy is determined by more than chronological age.

Relevant factors include:

  • Comorbidities.
  • Frailty.
  • Functional status.
  • Overall health.


48. Active Surveillance

Definition

Structured monitoring of known prostate cancer with the intention of providing curative treatment if meaningful progression develops.

Main Objective

Avoid unnecessary treatment and treatment-related complications in patients whose cancer is unlikely to threaten life in the near term.


49. Historical Active Surveillance Criteria

The original chapter refers to active surveillance as an option for very-low-risk and low-risk disease.

Classical favorable features include:

  • PSA below 10 ng/mL.
  • Clinical T1c.
  • Gleason 3 + 3.
  • Low number of positive biopsy cores.
  • Limited cancer involvement in each core.
  • Low PSA density.


50. Contemporary Low-Risk Management

Current EAU guidance recommends:

Active Surveillance for Low-Risk Localized Prostate Cancer in Patients With Life Expectancy Greater Than 10 Years.

Clinical Importance

Active Surveillance Is The Preferred Strategy For Most Suitable Patients With Low-Risk Prostate Cancer.


51. Selected Intermediate-Risk Active Surveillance

Current guidance also allows active surveillance for selected Grade Group 2 patients.

Favorable Features

  • Less than approximately 10% Gleason pattern 4.
  • PSA below 10 ng/mL.
  • Clinical stage no higher than cT2a.
  • Low tumour volume on imaging.
  • Limited positive biopsy cores.
  • No concerning adverse pathological patterns.

Important Qualification

These patients require careful counseling about an increased risk of progression compared with low-risk disease.

Clinical Importance

Grade Group 3 Disease Is Generally Not Suitable For Routine Active Surveillance.


52. Active Surveillance Follow-Up

Important components include:

  • PSA testing.
  • Clinical assessment.
  • Repeat MRI.
  • Repeat biopsy when indicated.

Contemporary EAU Framework

  • PSA at least every six months.
  • Repeat biopsy generally according to an individualized protocol, often every two to three years.
  • MRI and repeat biopsy when progression is suspected.

Clinical Importance

Changes in PSA or MRI alone do not necessarily establish pathological progression.

Biopsy Reclassification Remains An Important Reason To Move From Surveillance To Curative Treatment.


53. Watchful Waiting

Definition

Observation primarily intended to avoid unnecessary treatment and provide symptom-directed care when required.

Main Candidates

  • Limited life expectancy.
  • Significant competing health risks.
  • Patients unlikely to benefit from curative treatment.

Key Difference

Active Surveillance Preserves Curative Intent; Watchful Waiting Emphasizes Symptom Control.


54. Primary Androgen-Deprivation Therapy

Historical Source

The chapter describes primary ADT as rarely indicated for localized disease.

Possible Historical Circumstances

  • Symptomatic disease.
  • Extensive poorly differentiated cancer.
  • Short life expectancy.

Contemporary Principle

ADT Monotherapy Is Not Recommended As Routine Treatment For Asymptomatic Localized Prostate Cancer.

Clinical Importance

ADT does not replace established curative treatments in otherwise suitable patients.


55. Neoadjuvant ADT Before Radical Prostatectomy

Historical Recommendation

Not routinely recommended.

Contemporary Position

Routine neoadjuvant ADT before radical prostatectomy remains unsupported outside selected research settings.


56. Radical Prostatectomy

Definition

Surgical removal of the prostate and seminal vesicles, followed by reanastomosis of the bladder and urethra.

Main Goal

Curative treatment.

Appropriate Candidates

  • Selected localized prostate cancer.
  • Life expectancy generally exceeding 10 years.
  • Adequate operative fitness.
  • Informed preference for surgery.


57. Historical Surgical Approaches

The original chapter identifies:

  • Open retropubic prostatectomy.
  • Open perineal prostatectomy.
  • Laparoscopic radical prostatectomy.
  • Robot-assisted laparoscopic prostatectomy.


58. Robot-Assisted Radical Prostatectomy

Potential Benefits

  • Reduced blood loss.
  • Lower transfusion requirement.
  • Shorter hospital stay in some settings.
  • Enhanced operative visualization.

Important Qualification

Long-term oncological and functional outcomes depend heavily on surgeon experience.

Clinical Importance

The Expertise Of The Surgeon And Surgical Team Is A Major Determinant Of Radical Prostatectomy Outcomes.


59. Pelvic Lymph Node Dissection

Clinical Purpose

Determine pathological nodal status.

Historical Source Threshold

The chapter suggests lymph node dissection when predicted nodal metastasis risk is at least:

2%.

Important Qualification

This is a historical threshold.

Current decisions depend on contemporary prediction models, cancer risk, and the relevant guideline.

Contemporary Technical Principle

When lymph node dissection is performed under EAU guidance, an extended template is recommended.


60. Nerve-Sparing Radical Prostatectomy

Main Goal

Preserve erectile function by avoiding injury to neurovascular structures.

Historical Favorable Features

  • Good preoperative erectile function.
  • Clinical T1c.
  • PSA below 10 ng/mL.
  • Favorable Gleason grade.

Contemporary Considerations

  • MRI findings.
  • Cancer location.
  • Risk of extracapsular extension.
  • Baseline sexual function.
  • Patient preference.

Clinical Importance

Nerve Sparing Should Be Performed When Oncologically Appropriate, Rather Than Based On A Fixed PSA Or Gleason Threshold Alone.


61. Non-Nerve-Sparing Surgery

May be necessary when tumour characteristics raise concern for cancer extension into the neurovascular region.

Important Consequence

Higher likelihood of erectile dysfunction.


62. Radical Prostatectomy Outcomes

The historical source suggests similar cancer outcomes between appropriately performed open and minimally invasive approaches.

Contemporary Principle

Choice of technique should prioritize:

  • Cancer clearance.
  • Continence preservation.
  • Erectile function.
  • Surgeon experience.
  • Patient safety.


63. Surgery Versus Observation

The source describes historical trial findings suggesting limited survival differences in some lower-risk patient groups.

Important Qualification

Outcomes vary by:

  • Cancer risk.
  • Age.
  • Life expectancy.
  • Duration of follow-up.
  • Whether observation is active surveillance or less intensive monitoring.

Clinical Importance

The Absolute Survival Benefit Of Surgery Is Often Small In Patients With Indolent Cancer Or Substantial Competing Mortality Risk.


64. External-Beam Radiotherapy

EBRT.

Clinical Purpose

Deliver a cancer-eradicating radiation dose to the prostate while minimizing exposure of surrounding structures.

Main Techniques

  • Intensity-modulated radiotherapy.
  • Volumetric modulated arc therapy.
  • Image-guided radiotherapy.


65. Historical Radiation Doses

The source describes:

Low-Risk Disease

75–79 Gy

over approximately eight to nine weeks.

Intermediate- or High-Risk Disease

Up to:

81 Gy.

Important Qualification

These are historical conventional fractionation schedules, not universal modern prescriptions.


66. Contemporary Hypofractionation

Definition

Radiotherapy delivered in larger doses per fraction over fewer treatments.

Important Approaches

  • Moderate hypofractionation.
  • Ultra-hypofractionation.
  • Stereotactic body radiotherapy.

Clinical Importance

Moderately Hypofractionated Radiotherapy Is An Established Curative Treatment Option For Appropriate Patients With Localized Prostate Cancer.


67. Contemporary Moderate Hypofractionation Examples

Current European guidance includes regimens such as:

  • 60 Gy in 20 fractions.
  • 70 Gy in 28 fractions.

Important Qualification

Final prescription depends on risk group, treatment planning, technique, and organ-at-risk constraints.


68. Stereotactic Body Radiotherapy

SBRT.

Definition

Highly conformal radiation delivered in a small number of fractions.

Historical Source

Describes CyberKnife and other SBRT approaches as investigational.

Contemporary Position

SBRT is an established option for appropriately selected patients, particularly with favorable localized disease and suitable urinary function.

Important Clinical Principle

SBRT Is No Longer Exclusively An Investigational Technique, Although Patient Selection And Treatment Quality Remain Essential.


69. Radiotherapy and ADT

The addition of hormonal therapy depends on disease risk.

Low-Risk Disease

ADT is generally unnecessary.

Selected Intermediate-Risk Disease

Short-term ADT may improve outcomes.

High-Risk Disease

Long-term ADT is an important component of definitive radiotherapy.


70. Short-Term ADT

Typical Duration

4–6 Months.

Clinical Role

Used in appropriate intermediate-risk disease.

Important Qualification

Selected favorable intermediate-risk patients may omit ADT after individualized discussion.


71. Long-Term ADT

Typical Duration

2–3 Years.

Clinical Role

An established component of radiotherapy for high-risk localized prostate cancer.

Clinical Importance

Long-Term ADT Combined With Radiotherapy Improves Outcomes In Appropriate High-Risk Patients.


72. Pelvic Lymph Node Irradiation

Historical Source

The chapter describes uncertain routine benefit and ongoing trials.

Contemporary Clinical Context

Pelvic nodal radiation may be considered in selected patients with substantial risk of occult nodal disease.

Important Qualification

The benefit must be balanced against potential additional bowel and urinary toxicity.


73. Proton Beam Therapy

Definition

External-beam radiotherapy using protons.

Historical Position

The source states that routine use was not recommended.

Contemporary Clinical Context

Proton therapy is an available radiation modality in selected centers.

Important Qualification

It has not demonstrated consistent superiority over high-quality modern photon radiotherapy for all patients with localized prostate cancer.


74. Brachytherapy

Definition

Radiotherapy delivered by radioactive sources placed within the prostate.

Main Categories

  • Low-dose-rate brachytherapy.
  • High-dose-rate brachytherapy.


75. Low-Dose-Rate Brachytherapy

LDR.

Historical Sources

  • Iodine-125.
  • Palladium-103.

Historical Dose Examples

  • Iodine-125: 145 Gy.
  • Palladium-103: 125 Gy.

Clinical Role

Monotherapy for selected favorable localized disease, particularly patients with good urinary function.

Important Qualification

These are historical dose examples and should not be treated as universal prescriptions for every technique or isotope.


76. High-Dose-Rate Brachytherapy

HDR.

Historical Source

Iridium-192.

Technique

Temporary transperineal catheters deliver radiation to the prostate.

Clinical Role

May be used:

  • As a boost with EBRT.
  • As monotherapy in selected specialized settings.


77. Brachytherapy Combined With EBRT

The historical source describes combined treatment in intermediate- and high-risk disease.

Historical EBRT Component

Approximately:

40–50 Gy.

Additional Treatments

May include ADT.

Important Contemporary Principle

Brachytherapy boost may improve biochemical cancer control in selected higher-risk patients.

However, it can increase urinary adverse effects.


78. Brachytherapy Risk Factors

The historical source identifies increased toxicity risk with:

  • Previous TURP.
  • Large prostate gland.
  • Very small prostate gland.
  • Bladder outlet obstruction.

Historical Prostate Size Categories

  • Large gland: approximately 60–80 g.
  • Small gland: below approximately 20 g.

Important Qualification

Size alone is not a universal contraindication.

Modern treatment selection includes anatomical assessment, urinary symptoms, and technical feasibility.


79. Cryotherapy

Definition

Prostate tissue destruction using controlled freezing and thawing.

Historical Technique

The source describes:

  • Approximately 12–15 cryoprobes.
  • 17-gauge cryoneedles.
  • TRUS guidance.
  • Temperature sensors.
  • Urethral warming catheter.
  • Two freeze–thaw cycles.

Historical Temperature Target

Approximately:

−40°C.

Important Qualification

These are historical technical descriptions rather than universally applicable procedural instructions.


80. Historical Cryotherapy Candidate Selection

The source describes cryotherapy in selected patients:

  • Unsuitable for radical prostatectomy.
  • With limited life expectancy.
  • With prostate volume below approximately 40 mL.

Important Clinical Qualification

Primary cryotherapy is not generally recommended as routine standard treatment for localized prostate cancer.


81. High-Intensity Focused Ultrasound

HIFU.

Mechanism

Focused ultrasound produces thermal tissue injury.

Clinical Role

Used in selected prostate cancer ablative strategies.

Contemporary Qualification

Long-term comparative evidence remains less mature than for established radical treatment.


82. Vascular-Targeted Photodynamic Therapy

VTP.

Definition

Ablative therapy combining a photosensitizing agent with targeted light activation.

Historical Status

Investigational.

Contemporary Context

Remains a specialized treatment approach rather than routine first-line management.


83. Contemporary Position on Focal Ablation

Focal therapies may reduce certain functional adverse effects compared with whole-gland treatment.

However, concerns remain regarding:

  • In-field recurrence.
  • Untreated cancer elsewhere in the prostate.
  • Need for retreatment.
  • Long-term cancer control.
  • Lack of standardized surveillance.

Current European Recommendation

Whole-gland or focal ablative therapies should generally be offered within clinical trials or prospective registries.

Clinical Importance

Focal Therapy Should Not Automatically Be Presented As An Oncologically Equivalent Alternative To Radical Prostatectomy Or Radiotherapy.


84. Prognosis

Main Determinants

  • PSA.
  • ISUP Grade Group.
  • Clinical stage.
  • Tumour volume.
  • Surgical pathological findings if prostatectomy is performed.
  • Treatment response.

Clinical Importance

Localized Prostate Cancer Generally Has A Favorable Prognosis, But Outcomes Differ Substantially Between Low-, Intermediate-, And High-Risk Disease.


85. Historical Prognostic Tools

The source identifies:

  • Partin tables.
  • Memorial Sloan Kettering prediction tools.

Clinical Role

May estimate:

  • Probability of organ-confined disease.
  • Risk of extraprostatic extension.
  • Seminal vesicle involvement.
  • Lymph node involvement.
  • Treatment outcomes.

Important Qualification

Only appropriately updated and validated prediction models should be used for current decisions.


86. Radical Prostatectomy Complications

The original chapter reports a broad range of historical complications.

Intraoperative Complications

  • Rectal injury.
  • Major hemorrhage.
  • Rare perioperative mortality.

Postoperative Complications

  • Deep vein thrombosis.
  • Pulmonary embolism.
  • Lymphocele.

Long-Term Complications

  • Urinary incontinence.
  • Urethral or bladder neck stricture.
  • Erectile dysfunction.


87. Historical Prostatectomy Complication Rates

The source reports:

  • Rectal injury: 0–5%.
  • Major bleeding: 1–12%.
  • Mortality: 0–2%.
  • Deep vein thrombosis: 0–8%.
  • Pulmonary embolism: 1–8%.
  • Lymphocele: 1–3%.
  • Urinary incontinence: 0–50%.
  • Stricture: 2–9%.
  • Erectile dysfunction: 30–100%.

Important Qualification

These ranges represent heterogeneous historical cohorts, definitions, techniques, and follow-up periods.

They should not be interpreted as expected complication rates for a contemporary individual patient.

Clinical Importance

Functional Outcomes After Radical Prostatectomy Depend Strongly On Baseline Function, Cancer Extent, Surgical Technique, And Surgeon Experience.


88. Urinary Incontinence After Prostatectomy

Mechanism

May result from injury or functional impairment involving the urinary sphincter.

Possible Consequences

  • Stress urinary incontinence.
  • Pad use.
  • Reduced quality of life.

Clinical Importance

Preoperative continence counseling and postoperative pelvic floor rehabilitation are important.


89. Erectile Dysfunction After Prostatectomy

Mechanisms

  • Neurovascular injury.
  • Vascular changes.
  • Pre-existing erectile dysfunction.
  • Other postoperative factors.

Clinical Importance

Nerve-sparing surgery may improve the probability of erectile recovery, but does not guarantee it.


90. Radiotherapy Complications

Early Urinary Effects

  • Frequency.
  • Urgency.
  • Dysuria.
  • Irritative voiding symptoms.

Early Bowel Effects

  • Diarrhea.
  • Rectal irritation.
  • Rectal bleeding.
  • Urgency.


91. Historical Late Radiotherapy Toxicity

The source reports:

Late Genitourinary Toxicity

Approximately:

16%.

Late Gastrointestinal Toxicity

Approximately:

10%.

Important Examples

Genitourinary:

  • Hematuria.
  • Radiation cystitis.
  • Stricture.
  • Urinary incontinence.

Gastrointestinal:

  • Radiation proctitis.
  • Chronic diarrhea.
  • Rectal bleeding.
  • Rare severe bowel complications.

Important Qualification

These rates reflect historical treatment cohorts and toxicity definitions.

Modern image guidance and radiation planning can reduce some complications.


92. Secondary Malignancy Risk

The original source identifies an increased risk of secondary cancers following radiation.

Clinical Importance

Radiation-associated second malignancies are a possible late complication, although their absolute risk is generally low and must be balanced against the benefits of prostate cancer treatment.


93. Treatment Selection and Functional Outcomes

When choosing between surgery and radiation, discuss:

  • Urinary continence.
  • Erectile function.
  • Baseline urinary obstruction.
  • Bowel function.
  • Recovery time.
  • Possible need for additional treatment.
  • Long-term cancer control.

Clinical Importance

Patients Should Understand That Surgery And Radiation Have Different Functional Toxicity Profiles Even When Both Offer Effective Cancer Control.


94. Follow-Up After Definitive Treatment

Historical Source

The chapter recommends follow-up for at least:

10 Years.

Historical PSA Schedule

  • Every 6–12 months for five years.
  • Annually thereafter.

Clinical Importance

Long-term PSA monitoring is necessary because recurrence may develop years after curative treatment.


95. PSA After Radical Prostatectomy

Following complete removal of the prostate, PSA is expected to become undetectable or extremely low.

Historical Threshold

Below 0.1 ng/mL.

Biochemical Recurrence

Conventionally:

PSA ≥0.2 ng/mL with confirmation.

Clinical Importance

A Confirmed Rising PSA After Radical Prostatectomy May Indicate Recurrent Prostate Cancer.


96. PSA After Radiotherapy

PSA generally decreases gradually following radiation.

Historical Favorable Marker

PSA nadir below:

0.5 ng/mL.

Important Qualification

This is a favorable response marker rather than an absolute definition of cure.

Standard Biochemical Recurrence Definition

PSA Nadir + 2 ng/mL.


97. Follow-Up Examination

The source recommends annual DRE, with omission considered when PSA remains undetectable.

Contemporary Qualification

DRE and imaging should be individualized according to:

  • PSA trend.
  • Symptoms.
  • Treatment received.
  • Clinical suspicion.


98. Imaging During Follow-Up

Further imaging may be indicated for:

  • New bone pain.
  • Rapid PSA rise.
  • Short PSA doubling time.
  • Other symptoms suggesting recurrence.

Contemporary Options

  • PSMA PET/CT.
  • Pelvic MRI.
  • CT.
  • Bone scan in selected situations.

Clinical Importance

Routine imaging in asymptomatic patients with stable PSA is generally unnecessary unless results would change management.


99. Clinical and Surgical Pearls

Epidemiology and Risk

  • Localized prostate cancer represents a large proportion of newly diagnosed cases.
  • Risk increases with age.
  • Family history is important.
  • Many localized tumours are indolent.

Diagnosis

  • Localized disease is usually asymptomatic.
  • PSA is not cancer-specific.
  • DRE may identify a suspicious nodule.
  • Prostate MRI is important before biopsy.
  • Transperineal biopsy is preferred in current European guidance.

Risk Stratification

  • PSA, Grade Group, and clinical stage are essential.
  • Gleason 4 + 3 is more aggressive than 3 + 4.
  • Tumour volume influences treatment decisions.
  • Clinical T1–T2 disease can still be biologically high risk.

Active Surveillance

  • Preferred for suitable low-risk disease.
  • Selected favorable Grade Group 2 cancers may also qualify.
  • PSA and MRI changes require assessment.
  • Progression should be confirmed appropriately before changing treatment.

Surgery

  • Radical prostatectomy is an established curative treatment.
  • Nerve sparing is important when oncologically safe.
  • Surgeon experience strongly influences outcomes.
  • Continence and erectile function are major counseling priorities.

Radiotherapy

  • Modern EBRT is an established curative option.
  • Moderate hypofractionation is standard in appropriate patients.
  • SBRT is an option in selected patients.
  • Brachytherapy may be used alone or as a boost.
  • ADT is added according to cancer risk.

Focal Treatments

  • Cryotherapy and HIFU are specialized options.
  • Long-term comparative evidence remains limited.
  • Prospective registries or clinical trials are appropriate settings.


100. Essential Examination Principles

1. Define Localized Prostate Cancer

Clinical T1–T2, N0, M0.

2. Recognize That Localized Disease Is Usually Asymptomatic

Most diagnoses follow PSA-based investigation.

3. Understand PSA Limitations

Elevated PSA does not automatically indicate malignancy.

4. Use MRI Before Biopsy

MRI-directed assessment is central to modern diagnostic pathways.

5. Know the ISUP Grade Groups

Histological grade strongly influences management.

6. Distinguish Low- and High-Risk Localized Disease

Both may be T1–T2, but treatment requirements differ.

7. Offer Active Surveillance for Suitable Low-Risk Cancer

Avoid unnecessary radical treatment.

8. Distinguish Active Surveillance From Watchful Waiting

Active surveillance preserves the opportunity for cure.

9. Understand the Role of Life Expectancy

Curative treatment is generally more beneficial when life expectancy exceeds 10 years.

10. Know the Main Curative Treatments

Radical prostatectomy and radiotherapy.

11. Recognize Nerve-Sparing Principles

Preserve erectile neurovascular structures when oncologically safe.

12. Understand Pelvic Lymph Node Dissection

Use contemporary nodal risk assessment and appropriate surgical templates.

13. Know the Role of ADT With Radiation

Approximately 4–6 months for selected intermediate-risk disease and 2–3 years for high-risk disease.

14. Recognize Modern Hypofractionation

Radiation no longer routinely requires eight or nine weeks of treatment.

15. Understand Focal Therapy Limitations

HIFU and cryotherapy do not have the same maturity of long-term evidence as established radical treatments.

16. Counsel About Functional Complications

Urinary, sexual, and bowel outcomes matter greatly.

17. Continue Long-Term PSA Surveillance

Recurrence may occur many years after treatment.


101. Historical Clinical Context and Important Qualifications

Historical Incidence and Prevalence

The epidemiological figures are from older populations and should not be interpreted as current statistics.

Very High Age-Related Prevalence

The historical estimates of 44% and 83% likely reflect selected histological or autopsy-detected disease rather than clinically significant diagnosed prostate cancer.

Historical AUA Screening Recommendations

The source uses the 2013 screening framework.

Contemporary early detection is more individualized according to risk and life expectancy.

PSA Density Units

The historical source contains an inconsistent PSA density unit.

The conventional unit is ng/mL/cm³.

Imaging

The source emphasizes CT and bone scans using older risk thresholds.

Modern prostate MRI and PSMA PET have changed diagnosis and staging.

Antibiotic Prophylaxis

The source recommends antibiotics for every prostate biopsy.

Current European guidance permits omission for low-risk transperineal biopsy.

Historical Risk Categories

The source's three-tier classification does not fully reflect contemporary intermediate-risk subdivision and EAU five-tier risk classification.

Active Surveillance and Life Expectancy

The source's final pearl suggests active surveillance for low-risk patients with life expectancy below 10 years.

A more appropriate modern distinction is:

  • Active surveillance: Generally suitable for low-risk disease when life expectancy exceeds 10 years.
  • Watchful waiting: Generally appropriate for asymptomatic patients with life expectancy below 10 years.

Primary ADT

ADT monotherapy is not standard curative treatment for localized prostate cancer.

Surgical Outcomes

The historical complication ranges are broad and do not represent contemporary individualized risk.

Radiation Fractionation

The source's conventional eight- to nine-week schedules have been supplemented by established shorter treatment schedules.

Cryotherapy and HIFU

These are not routine replacements for standard curative therapy.

Brachytherapy

Historical dose prescriptions and gland-size criteria should be interpreted within current radiotherapy protocols.


102. Historical Diagnostic Codes

ICD-9

185

Malignant neoplasm of prostate.

V16.42

Family history of malignant neoplasm of prostate.

ICD-10 Codes Listed in the Source

C61

Malignant neoplasm of prostate.

Z80.42

Family history of malignant neoplasm of prostate.

Coding Qualification

These codes are preserved from the source. Actual clinical coding should follow the currently applicable coding system and confirmed diagnosis.


Final Urological Revision Summary

Localized prostate cancer is histologically confirmed adenocarcinoma clinically confined to the prostate, without regional lymph node or distant metastatic involvement.

Main Risk Factors

  • Increasing age.
  • Family history.
  • Hereditary cancer-predisposition variants.
  • Population-associated risk factors.
  • Other genetic and environmental influences.

Main Diagnostic Investigations

  1. PSA.
  2. Digital rectal examination.
  3. PSA density and other selected biomarkers.
  4. Multiparametric prostate MRI.
  5. Targeted and/or systematic biopsy.
  6. ISUP Grade Group.
  7. Appropriate metastatic staging when indicated.

Main Management Options

Low-Risk Disease

  • Active surveillance for suitable patients.
  • Watchful waiting when life expectancy is limited.

Selected Favorable Intermediate-Risk Disease

  • Active surveillance in carefully selected cases.
  • Radical prostatectomy.
  • Radiotherapy.

Unfavorable Intermediate-Risk Disease

  • Radical prostatectomy.
  • Radiotherapy, often with short-term ADT.
  • Selected brachytherapy combinations.

High-Risk Localized Disease

  • Radical prostatectomy in selected patients.
  • Radiotherapy with long-term ADT.
  • Selected brachytherapy boost.

Main Treatment Complications

  • Urinary incontinence.
  • Erectile dysfunction.
  • Urethral stricture.
  • Urinary irritation.
  • Radiation cystitis.
  • Radiation proctitis.
  • Bowel toxicity.
  • Surgical bleeding or thromboembolic events.

Prognostic Factors

  • PSA.
  • ISUP Grade Group.
  • Clinical stage.
  • Tumour volume.
  • Pathological findings.
  • Treatment response.
  • Patient health and life expectancy.

Follow-Up Priorities

  • Serial PSA.
  • Urinary function.
  • Erectile function.
  • Bowel symptoms after radiation.
  • Assessment for biochemical recurrence.
  • Additional imaging when clinically indicated.

The Central Urological Objective Is To Identify Clinically Significant Localized Prostate Cancer Accurately, Avoid Unnecessary Treatment Of Indolent Disease, Select Effective Curative Treatment According To Risk And Life Expectancy, Preserve Urinary And Sexual Function, And Maintain Long-Term Surveillance For Recurrence.

 

Image description
0 Comments